Jazz Pharmaceuticals

Jazz Pharmaceuticals earns a Neutral rating, with a composite score in the low 50s and conviction at one out of five. The pillar mix is sharply uneven: fundamentals lead in the high 80s, regulatory registers just below 50, editorial stands at 30, and market performance sits in the mid-teens. The fundamentals pillar benefits from top-tier gross-margin and market-cap subscores, an operating-margin subscore in the mid-90s, and a cash-runway subscore of 90. Those strengths offset a revenue-growth subscore near 69. Regulatory support remains moderate, reflecting a jurisdiction score of 50 and an enforcement subscore of 80, while weak filing cadence, limited market liquidity, and absent newsroom activity constrain the composite.

Licensed fundamentals data show year-over-year revenue growth of roughly 19%, establishing credible expansion without matching the strength of the profitability profile. Gross margin exceeds 91%, while operating margin approaches 24%, demonstrating substantial conversion from sales into operating profit. EBITDA stands slightly above $2.0 billion, net income remains positive, and the financial condition is stable. Market capitalization is approximately $15.3 billion, supporting the highest market-cap tier within the fundamentals assessment. Primary regulatory filings show no filing date in the captured cadence field, while no regulatory events appeared over either the prior 90-day or 180-day periods and no enforcement hits were recorded. Institutional pricing feeds show no captured trading volume, leaving the market pillar at 15, while CIN newsroom coverage records no newsroom or brief hits.

The forward catalyst rests squarely on fundamentals, the only pillar delivering a clearly differentiated score. Continued revenue expansion against a gross margin above 91% and an operating margin near 24% can reinforce earnings power and lift the composite even without immediate improvement in market or editorial inputs. A more consistent primary-filing cadence could add regulatory support, but it remains secondary to operating execution. The single most important signal to watch is whether year-over-year revenue growth sustains or exceeds the current roughly 19% pace while the elevated margin structure remains intact.